Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-05-17 | Mr. Geoffrey M. Glass, age 44, is the Chief Executive Officer and a member of the Board of Directors of Sancilio & Company, Inc.... It is anticipated that, upon election to our Board, Mr. Glass will join the Nominating and Corporate Governance Committee as its Chairman and the Audit and Compensation Committees as a member. He received no compensation from the Company during 2017. |
| 2019-04-30 | Mr. Geoffrey M. Glass, age 45, has been a member of the Board of Directors since July 2018 and became Chairman of the Board in December 2018... Mr. Glass brings to the Board and the Audit, Compensation and Nominating and Corporate Governance Committees over 24 years of experience. |
| 2020-04-27 | Geoffrey M. Glass, 46, has been a member of the Board of Directors since July 2018 and became Chairman of the Board in December 2018. Since May 2015, Mr. Glass has served as President of Clear Sciences, LLC, a management consulting company focused on life sciences industries. Since September 2019, Mr. Glass has also served as the Operating Partner at LongueVue Capital, an investment firm. Previously he was the Chief Executive Officer (from January 2018 through September 2018), and a member of the board of directors (from November 2017 through December 2018), of Sancilio Pharmaceuticals, a specialty pharma company. |
| 2021-04-30 | Geoffrey M. Glass, 47, Chair of the Board of Directors, Committees: (1)(2)(4), Compensation: $317,226 |
| 2022-04-29 | Geoffrey M. Glass, 48, has been a member of the Board since July 2018 and became Chair of the Board in December 2018. Since January 2021, Mr. Glass has served as the Chief Executive Officer of Kiniciti, LLC, a company that invests in non-therapeutic companies supporting cell and gene therapy innovation. Mr. Glass served as a member of the board of directors for Locus Biosciences, a biotechnology company that develops CRISPR-engineered precision antibacterial products, from August 2015 to October 2017. |
| 2023-04-28 | Geoffrey M. Glass, 49, has been a member of the Board since July 2018 and became Chair of the Board in December 2018. Since January 2021, Mr. Glass has served as the Chief Executive Officer of Kiniciti, LLC, a company that invests in non-therapeutic companies supporting cell and gene therapy innovation. He is also currently the Chairman of the Board at Ncardia, a drug discovery company focused on cardiovascular and neurological diseases, serving in that role since November of 2021. Further, since June of 2022, Mr. Glass has served as Chairman of the Board at Abzena, a biologics and bioconjugates development company. Mr. Glass has also been the Operating Partner at LongueVue Capital. Previously, he was the Chief Executive Officer (from January 2018 through September 2018), and a member of the board of directors (from November 2017 through December 2018), of Sancilio Pharmaceuticals, a specialty pharma company. |
| 2024-06-18 | Geoffrey M. Glass, 50, has been a member of the Board since July 2018 and became Chair of the Board in December 2018. The Board has an Audit Committee composed of Peter J. Thornton (Chair), Dr. Eric J. Ende, Geoffrey M. Glass and Dr. Mark A. McCamish. The Board has a Nominating and Corporate Governance Committee, composed of Dr. Eric J. Ende (Chair), Geoffrey M. Glass and Linda S. Palczuk. |
Data sourced from SEC filings. Last updated: 2026-02-08